

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zhongzhi Pharmaceutical Holdings Limited**

**中智藥業控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3737)**

### **POSITIVE PROFIT ALERT**

This announcement is made by the board of directors (the “**Board**”) of Zhongzhi Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 (“**FY2022**”), it is expected that the Group will record a significant increase in the net profit with net profit of around RMB110.0 million for FY2022 as compared to the net profit of approximately RMB52.4 million for the year ended 31 December 2021 (“**FY2021**”).

The expected increase in the net profit of the Group is mainly attributable to (i) a one-off impairment recognised in FY2021 of approximately RMB37.0 million in respect of the fair value loss on the unlisted wealth management product, while no such impairment was made in FY2022; and (ii) an improvement in the overall control of operational efficiency.

The information set out in this announcement is only based on the information currently available to the Board and the Board’s preliminary assessment of the unaudited consolidated management accounts of the Group for FY2022. The unaudited consolidated results of the Group for FY2022 are expected to be announced by the Company before the end of March 2023. Shareholders and potential investors are advised to read the annual results announcement of the Company when it is published.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Zhongzhi Pharmaceutical Holdings Limited**  
**Mr. Lai Zhi Tian**  
*Chairman and Executive Director*

Hong Kong, 18 January 2023

*As at the date of this announcement, the Board comprises nine directors. The executive directors are Mr. Lai Zhi Tian, Mr. Lai Ying Feng, Mr. Lai Ying Sheng and Mr. Cao Xiao Jun. The non-executive directors are Ms. Jiang Li Xia and Mr. Peng Zhiyun. The independent non-executive directors are Mr. Ng Kwun Wan, Mr. Wong Kam Wah and Mr. Zhou Dai Han.*